Your browser is no longer supported. Please, upgrade your browser.
APRE Aprea Therapeutics, Inc. daily Stock Chart
Aprea Therapeutics, Inc.
Index- P/E23.79 EPS (ttm)1.25 Insider Own12.94% Shs Outstand21.05M Perf Week6.30%
Market Cap634.31M Forward P/E- EPS next Y-2.98 Insider Trans-38.27% Shs Float18.32M Perf Month-12.62%
Income-34.00M PEG- EPS next Q-0.60 Inst Own83.80% Short Float6.32% Perf Quarter-9.78%
Sales- P/S- EPS this Y-64.90% Inst Trans-7.11% Short Ratio7.14 Perf Half Y-21.73%
Book/sh5.38 P/B5.52 EPS next Y-25.20% ROA- Target Price39.00 Perf Year-
Cash/sh5.74 P/C5.18 EPS next 5Y- ROE- 52W Range15.10 - 53.11 Perf YTD-35.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.06% Beta-
Dividend %- Quick Ratio10.80 Sales past 5Y- Gross Margin- 52W Low96.75% ATR1.89
Employees13 Current Ratio10.80 Sales Q/Q- Oper. Margin- RSI (14)52.81 Volatility3.97% 6.47%
OptionableNo Debt/Eq0.00 EPS Q/Q85.00% Profit Margin- Rel Volume0.40 Prev Close29.71
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume162.34K Price29.71
Recom2.20 SMA205.21% SMA50-4.13% SMA200-9.34% Volume0 Change0.00%
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Jul-16-20 07:00AM  
Jul-01-20 10:32AM  
Jun-29-20 07:00AM  
Jun-12-20 04:15PM  
Jun-11-20 10:44PM  
Jun-10-20 09:39AM  
Jun-03-20 08:00AM  
May-27-20 09:21AM  
May-18-20 08:00AM  
May-15-20 07:30AM  
May-11-20 10:57AM  
Apr-27-20 07:00AM  
Apr-06-20 08:00AM  
Apr-02-20 06:11AM  
Mar-26-20 08:00AM  
Feb-13-20 08:00AM  
Jan-30-20 07:30AM  
Jan-09-20 08:00AM  
Jan-03-20 05:56AM  
Dec-17-19 10:08AM  
Dec-12-19 08:30AM  
Dec-09-19 11:00AM  
Dec-07-19 08:35AM  
Nov-29-19 09:24AM  
Nov-14-19 04:15PM  
Nov-11-19 04:40PM  
Nov-06-19 09:15AM  
Oct-11-19 05:01PM  
Oct-08-19 03:59PM  
Oct-07-19 04:15PM  
Oct-03-19 11:09AM  
Oct-02-19 11:03PM  
Sep-30-19 10:21AM  
Sep-23-19 08:55AM  
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KDev Investments AB10% OwnerJul 07Sale34.55241,7038,350,8391,992,586Jul 07 05:41 PM
ROCKLAGE SCOTT MDirectorJun 16Sale33.30120,1644,001,46175,965Jun 18 07:23 PM
5AM Ventures IV, L.P.10% OwnerJun 16Sale33.30140,0004,662,00075,965Jun 18 07:22 PM
ROCKLAGE SCOTT MDirectorJun 11Sale28.75245,0007,044,41280,772Jun 15 09:13 PM
5AM Ventures IV, L.P.10% OwnerJun 11Sale28.75245,0007,044,41280,772Jun 15 09:12 PM
ROCKLAGE SCOTT MDirectorMay 19Sale35.15255,0008,963,25090,572May 21 09:32 PM
5AM Ventures IV, L.P.10% OwnerMay 19Sale35.15255,0008,963,25090,572May 21 09:31 PM
KDev Investments AB10% OwnerApr 13Sale31.25210,5486,579,6252,234,289Apr 15 09:18 AM